Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Jul 14, 2024; 30(26): 3210-3220
Published online Jul 14, 2024. doi: 10.3748/wjg.v30.i26.3210
Table 1 Basic demographics of the study population
Features
n of 605
%
Age, mean ± SD (58.2 ± 19), median = 60
< 60 years29448.6
≥ 60 years31151.4
Sex
Female29749.2
Male30750.8
Duration of symptoms
< 30 days 33062.6
30-59 days7513.2
60-89 days117.3
≥ 90 days149.3
Control without alarm features9215.2
Patients with alarm features51384.8
Alarm features
Upper GI bleeding14423.8
Unexplained weight loss13722.6
Persistent vomiting12420.5
Iron deficiency anemia508.3
Dysphagia376.1
Odynophagia50.8
Epigastric mass or lymphadenopathy10.2
Endoscopic finding
Patients without endoscopic finding43171.2
Patients with any endoscopic finding174 28.8
Peptic ulcer disease92 15.2
Erosive esophagitis class B or higher345.6
Malignancy426.9
Stricture10.2
Finding requiring specific therapy152.5
Medications
PPIs17329
Statins19132.3
Aspirin11118.8
Anticoagulant396.6
Anti-aggregate305.1
NSAIDs233.9